CD8+ T cell expansion in CLL patients treated with ibrutinib

Maria Joao Baptista, PharmD, PhD, Josep Carreras Leukaemia Research Institute, Barcelona, Spain, highlights the results of a study evaluating the T-cell repertoire in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Ibrutinib was found to induce a more oligoclonal T cell receptor (TCR) repertoire in patients with chronic lymphocytic leukemia (CLL), driven by expansion of specific CD8+ clonotypes. This study supports the investigation of therapeutic strategies combining ibrutinib with T- cell-directed immunotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).